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Abstract
Background Tacrolimus is an important immunosuppressive agent with high intra- and inter-individual pharmacokinetic vari-
ability and a narrow therapeutic index. As tacrolimus extensively accumulates in erythrocytes, hematocrit is a key factor in the
interpretation of tacrolimus whole blood concentrations. However, as hematocrit values in pediatric kidney transplant patients are
highly variable after kidney transplantation, translating whole blood concentration targets without taking hematocrit into con-
sideration is theoretically incorrect. The aim of this study is to evaluate the potential impact of hematocrit correction on tacrolimus
target exposure in pediatric kidney transplant patients.
Methods Data were obtained from 36 pediatric kidney transplant patients. Two hundred fifty-five tacrolimus whole blood
samples were available, together responsible for 36 area under the concentration-time curves (AUCs) and trough concentrations.
First, hematocrit corrected concentrations were derived using a formula describing the relationship between whole blood con-
centrations, hematocrit, and plasma concentrations. Subsequently, target exposure was evaluated using the converted plasma
target concentrations. Ultimately, differences in interpretation of target exposure were identified and evaluated.
Results In total, 92% of our patients had lower hematocrit (median 0.29) than the reference value of adult kidney transplant
patients. A different evaluation of target exposure for either trough level, AUC, or both was defined in 42% of our patients, when
applying hematocrit corrected concentrations.
Conclusion A critical role for hematocrit in therapeutic drug monitoring of tacrolimus in pediatric kidney transplant patients is
suggested in this study. Therefore, we believe that hematocrit correction could be a step towards improvement of tacrolimus dose
individualization.
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Introduction
Calcineurin inhibitors (CNIs) are the cornerstone of immuno-
suppressive therapy after kidney transplantation. Tacrolimus
was introduced in the 1990s as an alternative to ciclosporin
and is now widely used to prevent rejection after solid-organ
transplantation in both adult and pediatric transplant recipients
[1]. At the time of discharge after transplantation, approxi-
mately 70% of pediatric kidney transplant patients are treated
with tacrolimus [2]. Tacrolimus is characterized by a narrow
therapeutic index: high concentrations are associated with tox-
icity, malignancy, and infection, while low concentrations are
associated with an increased risk of acute rejection [3, 4].
Furthermore, the intra- and inter-individual pharmacokinetic
variability is high [1, 5]. Previously, body weight [6–8],
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CYP3A5 polymorphisms [6–9], age [9, 10] and hematocrit
level [6, 7] were found to have significant effects on pharma-
cokinetic variability in pediatric kidney transplant patients,
especially in the early phase after transplantation. Due to the
large pharmacokinetic variability, individualizing tacrolimus
dosing regimens by performing therapeutic drug monitoring
(TDM) to optimize the therapeutic effect and minimize ad-
verse effects is essential and currently the standard of care.
For pediatric kidney transplant patients, little is known
about the optimal targets for tacrolimus exposure.
Furthermore, both whole blood trough concentrations and ar-
ea under the concentration-time curves (AUCs) are used to
adjust the tacrolimus dosing regimen of the individual patient.
As it stands, it is unknown what the best pharmacokinetic
parameter to predict treatment outcome is, and the relationship
between blood trough concentrations and AUCs in pediatric
patients remains a matter of debate [10]. As reference values
for target exposure based on clinical trials in pediatric patients
are lacking, adult targets are currently used [3, 11, 12]. Yet,
large differences exist between the pediatric and adult popu-
lation in terms of pharmacokinetics and physiology [13].
Hematocrit is a confounder for interpretation of tacrolimus
exposure in whole blood. Several population pharmacokinetic
studies have indeed identified hematocrit as a key factor for
interpretation of tacrolimus whole blood concentrations in
both the adult and pediatric population [6, 14, 15]. Low he-
matocrit results in lower whole blood exposure and can then
be incorrectly interpreted as an increased apparent clearance
of tacrolimus from whole blood, while the plasma concentra-
tions and clearance remain unchanged [6, 7]. Currently, tacro-
limus is generally measured as total concentrations in whole
blood, whereas only the unbound concentration in plasma is
pharmacologically active as it is available for cellular diffu-
sion and distribution [16]. Measurement of plasma or un-
bound tacrolimus concentrations might therefore be a better
reflection of the pharmacologically active drug, which is tech-
nically challenging and often unavailable in clinical practice
[3, 17]. Tacrolimus extensively accumulates in erythrocytes,
and the concentration in whole blood is the weighted average
concentration of the plasma and erythrocyte fractions.
Consequently, a change in hematocrit will affect the whole
blood concentration, without affecting the pharmacologically
active unbound plasma concentration [16, 18, 19].
Hematocrit values tend to change significantly in the first
months after transplantation [14, 20]. Changes in hematocrit
values can occur in both ways: most patients will have an
increase in hematocrit as erythropoietin levels increase rapidly
after a successful kidney transplantation. However, a decrease
is also possible for both early after transplantation based on
blood loss due to the surgery or dilution due to intensive fluid
control and after discharge as a side effect of the frequently
used concomitant immunosuppressive agent mycophenolic
acid. As tacrolimus trough concentrations and AUCs are
currently measured in whole blood, this may lead to incorrect
dose adjustments and inadequate tacrolimus exposure [21].
The aim of our study was to evaluate the potential impact of
hematocrit correction on tacrolimus target exposure in pediat-
ric kidney transplant patients.
Methods
Study design
To evaluate the impact of hematocrit correction on tacrolimus
dose individualization in pediatric kidney transplant patients,
we performed a retrospective cohort study at our tertiary re-
ferral center (Radboudumc Amalia Children’s Hospital,
Nijmegen) in the Netherlands.
Setting and subjects
Pediatric kidney transplant patients (aged 1–18 years) under-
going therapeutic drug monitoring for tacrolimus between
2012 and 2017 were included when an AUC0–12 h or
AUC0–8 h was available. A subset of our study population
has previously been described by Martial et al. [22]. Patients
were excluded in cases where a hematocrit value was not
available within 2 days of sampling. Sampling for the AUCs
was typically performed at the following time points: pre-dose
and 1, 2, 3, 4, 8, and 12 h after tacrolimus intake. All patients
received oral capsules (Prograft, Astellas Pharma) or a suspen-
sion (as extemporaneous preparation). Tacrolimus doses were
adjusted based on TDM to achieve the whole blood target
exposure that depends on time post transplantation and the
immunosuppressive regimen of choice, as shown in Table 1
and Table 2 [3, 11, 12, 23, 24]. In our hospital, two treatment
regimens with tacrolimus are commonly used: a prednisolone-
free immunosuppressive regimen (according to the TWIST
protocol) [25] or a triple therapy including prednisolone and
mycophenolate mofetil [3]. As food may decrease the rate and
extent of tacrolimus absorption, patients were instructed to
always take the medication in an identical manner (either with
or without food). The Ethics Committee of the Radboud
UniversityMedical Center waived the need for ethical approv-
al according to the Dutch Law on Human Research, as only
patient chart data were collected.
Step 1: Derivation of hematocrit corrected target exposure
As tacrolimus dose individualization in children is guided
by measurement of whole blood concentrations [3], we de-
rived the associated plasma trough concentrations and plasma
AUCs to use as hematocrit corrected target exposure. Whole
blood concentrations (Cwb) can be calculated from plasma
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concentrations, using the fraction of hematocrit (fHCT) for
weighting with the following equation (Eq. 1), in which
Bmax is the maximum binding concentration of 418 μg/L
and Kd is the dissociation constant of 3.8 μg/L [15]:
Equation 1 can be rearranged to calculate the plasma con-
centrations if the whole blood concentration and fraction he-
matocrit are known, with the following equation (Eq. 2):
For calculation of the plasma target concentrations we as-
sumed a fHCT of 0.35 L/L in the adult population, based on
hematocrit values found in previous studies conducted in adult
kidney transplant recipients [14, 26–28].
Converted plasma target trough concentrations
Subsequently, whole blood target trough concentrations were
converted to plasma target trough concentrations using the
aforementioned Eq. 2. The target ranges for converted plasma
trough concentrations and whole blood trough concentrations
with different hematocrit values are shown in Table 1. To fur-
ther illustrate the influence of hematocrit, a nomograph (Fig. 1)
is created using Eq. 2, in which the relationship between whole
blood tacrolimus concentrations and plasma tacrolimus concen-
trations for different hematocrit levels is shown.
Converted plasma target AUCs
Whole blood target AUCs cannot be directly converted to
plasma target AUCs, due to the non-linear binding of tacro-
limus and thus a varying blood-to-plasma ratio during a
dosing interval. Therefore, the individual whole blood
Table 1 Target whole blood concentrations and predicted plasma concentrations for tacrolimus using different hematocrit values
Time post-
transplantation
Target range
wba (μg/l)
Predicted target range
plasma (μg/l)
Predicted target
range wb (μg/l)
Predicted target
range wb (μg/l)
literature
Ht = 0.35
literature
Ht = 0.35
Ht = 0.30 Ht = 0.25
Target trough level (C0) prednisolone-free
regimen
0–4 weeks 10–20 0.27–0.58 8.6–17.2 7.2–14.5
4 weeks–6 months 5–15 0.13–0.42 4.3–12.9 3.6–10.8
6–12 months 5–10 0.13–0.27 4.3–8.6 3.6–7.2
> 12 months 4–8 0.10–0.21 3.4–6.9 2.9–5.8
Target trough level (C0) immunosuppressive
regimen including prednisolone
0–4 weeks 10–15 0.27–0.42 8.6–12.9 7.2–10.8
4 weeks–6 months 7–12 0.19–0.33 6.0–10.3 5.1–8.7
6–12 months 5–10 0.13–0.27 4.3–8.6 3.6–7.2
> 12 months 4–8 0.10–0.21 3.4–6.9 2.9–5.8
AUC area under the concentration time curve, C0 trough concentration, wb whole blood
a Targets according to our local hospital protocol which is based on the following references: [23, 3, 24, 11]
Fig. 1 Nomograph of predicted
tacrolimus plasma trough
concentrations corrected for
hematocrit
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Cp ¼
Cwb−KD−Bmax∙ f HCT þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Bmax∙ f HCT þ KD−Cwbð Þ2 þ 4∙Cwb∙KD
q
2
Cwb ¼ Cp∙ 1þ Bmax∙ f HCTCp þ KD
 
concentrations on which the target AUCs are based should
be converted to plasma concentrations, and subsequently,
the plasma target AUC can be calculated. In the literature,
however, these individual whole blood concentrations for
the AUC targets are not available. Therefore, we simulated
the steady-state whole blood pharmacokinetics of tacroli-
mus in 1000 virtual adult patients, based on a previously
validated population pharmacokinetic model for tacrolimus
[29] with the software package NONMEM V7.4.1. For cal-
culation of the AUCs, we integrated the predicted whole
blood concentrations and plasma concentrations versus
time during a 12-h dosing interval for all 1000 individuals.
A power trend line fitted our data best (R squared coefficient
of 0.93, Supplementary Fig. 1). Subsequently, plasma target
AUCs were calculated using the corresponding formula y =
0.0218x1.0772, where y and x represent the plasma target
AUC and whole blood target AUC, respectively. The target
ranges for whole blood AUCs and converted plasma AUCs
are shown in Table 2.
Step 2: Derivation of hematocrit corrected trough concen-
trations and AUCs of the patients
Whole blood trough concentrations of the patients were
converted to plasma trough concentrations using the afore-
mentioned Eq. 2. Whole blood AUCs were converted to plas-
ma AUCs by converting the individual concentrations of dif-
ferent time points on which the total AUC0–12 h was based.
Step 3: Evaluation of target exposure
Subsequently, whole blood AUCs and trough concentra-
tions of the patients as well as predicted plasma AUCs and
trough concentrations of the patients were compared with the
corresponding target concentrations.
Step 4: Evaluation of differences in interpretation of target
exposure
Finally, to evaluate the impact of hematocrit correction in
TDM of tacrolimus, differences in the interpretation of target
exposure were identified by comparing the evaluation of
target exposure for whole blood concentrations with and with-
out hematocrit correction.
Data collection
A validated liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) bioanalytical assay was used to
determine tacrolimus whole blood concentrations. The
range of the assay was 1–300 μg/L. Intra-assay precision
and accuracy was 3.4%, 2.2%, 3.0% and 102%, 94%, and
94%, respectively, at 3.04, 6.23, and 13.0 μg/L (n = 6),
respectively [22, 30]. Furthermore, the following baseline
characteristics were collected from the electronic patient
records: age at kidney transplantation, gender, ethnicity,
time post transplantation, donor type (living or deceased),
height, and body weight. In addition, several laboratory
data were collected: hematocrit, blood hemoglobin, serum
creatinine, and serum urea. The estimated glomerular filtration
rate (GFR) was calculated with the adapted Schwartz formula
(K × height (cm)/serum creatinine (μmol/L)) with a k value of
36.5 [31]. Variables missing on the day of sampling were
obtained by selecting the value closest to this date with a
maximum for hematocrit of 2 days.
Data analysis
Baseline variables were summarized using median and
interquartile range (IQR). Whole blood trough concentra-
tions were evaluated using the target concentrations ac-
cording to our local hospital protocol. As shown in
Table 1, target concentrations vary with time after trans-
plantation and concomitant immunosuppressive medica-
tion [3, 11, 23, 24]. Furthermore, the whole blood AUCs
were compared to the AUC0–12 h target range of 210 ±
20% μg h/L up to 6 weeks post-transplantation and 125 ±
20% μg h/L upon 6 weeks post-transplantation (Table 2)
[3, 12]. The AUCs0–12 h were calculated using the linear-
log trapezoidal method. To adequately compare the indi-
vidual AUCs to the target AUC, the estimated AUC0–8 h
was extrapolated to an AUC0–12 h.
Table 2 Target whole blood
AUCs and predicted plasma
AUCs
Time
post-transplantation
Target wb
AUC0–12 h
(range)a
Target plasma
AUC0–12 h
(range)
Target AUC0–12 h 0–6 weeks 210 h μg/l (168–252) 6.9 h μg/l (5.4–8.4)
> 6 weeks 125 h μg/l (100–150) 4.0 h μg/l (3.1–4.8)
AUC area under the concentration time curve, wb whole blood
a Targets according to our local hospital protocol which is based on the following references: [3, 8]
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Results
Study population
A total of 37 children (age range 1.8–17.1 years) were eligible
for inclusion in this study. One patient was excluded because
the closest hematocrit value was 18 days before sampling.
Data on a total of 255 tacrolimus whole blood concentrations
were available, together providing 36 AUCs. Patient charac-
teristics are presented in Table 3. The AUCs and trough levels
were measured at any time post transplantation, predominant-
ly in the first 2 weeks after transplantation. Of note, 33 of the
36 patients (92%) had a lower hematocrit value (median 0.29)
than the reference hematocrit value of adult kidney transplant
patients of 0.35 L/L on which the current recommendations of
the dosing guidelines are based.
Step 1 and 2
For every individual patient, a whole blood AUC0–12 h (range
62–354 h μg/L) and whole blood trough concentration (range
2.0–25.7 μg/L) were converted to the corresponding plasma
AUC0-12h (range 2.0–16.0 h μg/L) and plasma trough concen-
tration (range 0.06–1.02 μg/L). Figure 2 shows the target
AUCs and target trough concentrations, whole blood and pre-
dicted plasma AUC0–12 h, and whole blood and predicted
plasma trough concentration of the individual patient.
Step 3
Furthermore, Fig. 2 shows the evaluation of the AUCs and
trough concentrations of the patients when compared to the
corresponding target whole blood and predicted plasma
ranges. Of the whole blood AUCs, 69% (25/36) were outside
the target range, compared to 58% (21/36) of the whole blood
trough concentrations. For the predicted plasma AUCs and
trough concentrations, similar numbers were found (69%
and 61%, respectively).
Step 4
Using the hematocrit corrected target levels, a different eval-
uation for target exposure for either the trough level, AUC or
both, was defined in a total of 42% (15/36) of our pediatric
kidney transplant patients. In Table 4, the number of whole
blood and predicted plasma values in and out of range are
shown. For the AUCs, a different evaluation of target expo-
sure was found in 22% (8/36) of the cases. For the trough
concentrations, a different evaluation was shown in 33%
(12/36) of the patients.
Discussion
Tacrolimus is a key immunosuppressive agent in the majority
of pediatric kidney transplant patients. This study shows the
importance of hematocrit correction in tacrolimus target eval-
uation in this population. Using hematocrit corrected target
concentrations, a different interpretation of tacrolimus expo-
sure was found in 42% of our patients. As tacrolimus has a
narrow therapeutic index, indicating that small variations in
drug exposure can have a relevant impact on graft survival and
toxicity, the results of this study suggest that using hematocrit
corrected targets could prevent incorrect dose adjustments of
tacrolimus based on whole blood concentrations. As the ma-
jority of our patients had a lower hematocrit value than the
reference value of adult kidney transplant patients of 0.35 L/L,
which causes an underestimation of the pharmacologically
active concentration, toxicity in particular may be prevented.
Currently, therapeutic target ranges for tacrolimus exposure
in pediatric kidney transplant patients are based on empirical
observations in adult transplant patients, as reference values
based on clinical trials in pediatric patients are lacking [3, 12].
Especially at the time of kidney transplantation, hematocrit
values are generally low and tend to change significantly in
the first months after transplantation. This underlines the need
to take this into account in the TDM of kidney transplant
patients [14, 20]. Moreover, this study shows that in our pop-
ulation hematocrit levels are significantly decreased and effort
should be made to adequately correct hematocrit in these
patients.
Table 3 Patient characteristics
n (%) Median IQR
Number of study participants 36
Age at time of transplantation (years) 8.3 4.3–14.9
Gender (n)
Male 21 (58)
Female 15 (42)
Ethnicity (n)
Caucasian 34 (94)
African 2 (6)
Time post transplantation (days) 12 9–13
Donor
Living 26 (72)
Deceased 10 (28)
Height (cm) 124.4 95.0–160.9
Total body weight (kg) 23.1 15.7–46.2
Laboratory measurements
Hematocrit (l/l) 0.29 0.26–0.31
Blood hemoglobin (mmol/l) 6.2 5.5–6.7
Serum creatinine (μmol/l) 55 37–103
Serum urea (mmol/l) 6.4 5.1–10.4
eGFR (ml/min/1.73 m2) 85 52–123
eGFR estimated glomerular filtration rate
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The importance of hematocrit correction in adult kidney
transplant patients has been highlighted previously [14, 27,
32]. Størset et al. developed a population pharmacokinetic
model for tacrolimus dosing in kidney transplant patients
and recommend to standardize tacrolimus whole blood con-
centrations to a hematocrit of 45% to reflect the unbound
(active) drug more closely, showing that hematocrit is a con-
founder and not a covariate for tacrolimus pharmacokinetics
[14, 27]. Furthermore, a pharmacokinetic study conducted by
De Jonge et al. indicated that hematocrit explained 4–14% of
variability in tacrolimus pharmacokinetic parameters [32].
The challenge for clinicians to attain the optimal target
exposure in the individual patient after kidney transplantation
has been previously described by Ekberg et al. and Størset
et al., who found 50% and 42%, respectively, of tacrolimus
trough concentrations outside the target range during the first
6–8 weeks post transplantation [14, 33]. Our data show even
higher percentages of AUCs and trough concentrations out-
side the proposed target range, underlining the large inter-
individual variability and challenge for clinicians to attain
the optimal target concentration.
To our knowledge, this is the first study investigating the role
of hematocrit in the interpretation of tacrolimus whole blood
exposure in pediatric kidney transplant patients in clinical prac-
tice. As the optimal strategy for TDM is still under debate, both
AUC and trough concentrations are currently used in the clin-
ical setting. Reported correlations between tacrolimusAUC and
trough concentration are variable, indicating that trough
Fig. 2 Whole blood and predicted
plasma AUCs0–12 h and trough
concentrations compared to the
target whole blood and predicted
target plasma concentrations
Table 4 Number of whole blood
and predicted plasma AUCs and
trough concentrations in and out
of range
AUC0–12 h
wb in range
AUC0–12 h
wb out of range
C0 wb
in range
C0 wb
out of range
Plasma—in range 7 4 9 5
Plasma—out of range 4 21 6 16
Total 11 25 15 21
AUC area under the concentration time curve, C0 trough concentration, wb whole blood
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concentrations alone may be a poor predictor of exposure [34].
A pharmacokinetic study previously conducted in a small sub-
set of our study population, recommends the use of AUC as a
driver for dose adaptations rather than trough concentrations in
very young pediatric kidney transplant patients [22]. One of the
strengths of this study is that both AUC and trough concentra-
tions were evaluated to make the results as broadly applicable
as possible. Unfortunately, there is no consensus among trans-
plant centers on the optimal tacrolimus target exposure [1]. The
target concentrations in our center are based on European con-
sensus guidelines [3]; however, as target concentrations vary
among centers, the predicted plasma target concentrations
should be adjusted according to local clinical practice.
An important limitation of our study is its retrospective de-
sign, whichmay cause information bias. Although the observed
whole blood concentrations were evaluated retrospectively, the
exact time of dose administration was known in 35/36 of our
patients. For one patient, the approximate time of dose admin-
istration was recorded in the medical file. As all patients were
admitted to the hospital during the time of sampling and med-
ication was administered by the nursing staff, we believe that
the adherence to the medication is good and therefore full com-
pliance was presumed. Due to the retrospective design of this
study, laboratory values of 15 patients were unavailable on the
day of sampling; therefore, these variables were imputed by
choosing value closest to the day of sampling with a maximum
of 2 days for hematocrit. This, however, is a limitation of our
study and ideally all samples would be paired.
In this study, values for the binding capacity (Bmax) and
affinity constant (Kd) were obtained from a previously con-
ducted study in adult liver transplant patients [15]. In addition,
Zahir et al. found similar values for Bmax and Kd in 40 liver
transplant recipients using the same equation [35]. Recently,
Størset et al. also used Eq. 2 to estimate the pharmacokinetic
disposition parameters to develop a theory-based population
pharmacokinetic model of tacrolimus in adult kidney trans-
plant patients [27]. As our study involves pediatric kidney
transplant patients, these values should ideally be obtained
from this specific population by determination of the
blood:plasma ratios of tacrolimus concentrations in pediatric
kidney transplant recipients using the equation previously de-
scribed by Piekoszewski et al. and Jusko et al. [15, 36].
As previously mentioned, the confounding effect of hemato-
crit variability can have a significant impact on the evaluation of
tacrolimus whole blood concentrations as tacrolimus is highly
bound to erythrocytes. As 99% of tacrolimus in plasma is bound
to proteins, mainly albumin and α-1-acid glycoprotein, this
could hold true for variations in albumin concentrations as well
[1]. Although previous research showed no influence of albumin
on whole blood tacrolimus concentrations in adult kidney trans-
plant patients [14], this should be evaluated in pediatric kidney
transplant patients as well. The influence of albumin was not
evaluated in the current study, because on the day of sampling
albumin concentrations were available for only eight of our
patients. Furthermore, due to low patient numbers and tight
monitoring, Bhard^ clinical endpoints (e.g., toxicity, rejection,
or infection) could not be identified in our study population.
For pediatric kidney transplant recipients, long-term graft
survival is especially important. Clinical trials in pediatric kid-
ney transplant patients to obtain the optimal target exposure are
however scarce [3]. As it is difficult to conduct clinical trials
with Bhard^ clinical endpoints in small patient groups, we feel
that all available information should be used to optimize TDM
in pediatric patients. Although technically challenging, mea-
suring both total and unbound tacrolimus concentrations in the
plasma of pediatric kidney transplant patients would be an
important opportunity for future research. Nonetheless, as ta-
crolimus is known to show high affinity for erythrocytes, we
advocate a critical role for hematocrit correction in TDM of
tacrolimus in pediatric kidney transplant patients. We consider
the current study a proof-of-concept that hematocrit correction
may be of added value in dose individualization of tacrolimus,
especially in the pediatric population. In future studies, there-
fore, effort should be made to characterize Bmax and Kd in
pediatric kidney transplant patients and to prospectively inves-
tigate the impact of hematocrit correction on clinical endpoints.
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